MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- BSE Healthcare
- Losers Today
Losers Today 
:
BSE Healthcare
Here are the top losers today from the BSE Healthcare index. To know more about the Index, please visit the BSE Healthcare Live Chart. Also read our detailed report on the pharmaceuticals sector.
Date: Jun 5, 2020 (Close)
Covid-19 Special 3x Opportunity: Five "Essential" Stocks to Buy Before the Lockdown Ends...
| COMPANY | PRICE (Rs) | CHANGE (%) | VOLUME ('000) | DAY'S H/L (Rs) | 52-WEEK H/L (Rs) | GET MORE INFO |
|---|---|---|---|---|---|---|
| S&P BSE SENSEX | 34,287.24 | 0.9% | - |
34,405 / 33,958 |
42,274 / 25,639 |
More Info
|
| NIFTY 50 | 10,142.15 | 1.1% | - |
10,178 / 10,041 |
12,431 / 7,511 |
More Info
|
| S&P BSE HEALTHCARE | 16,158.68 | 0.4% | - |
16,325 / 16,132 |
16,325 / 10,948 |
More Info
|
| DISHMAN CARBOGEN AMCIS LTD | 71.85 | -2.3% | 81.7 | 79 / 71 | 258 / 46 | More Info
|
| POLY MEDICURE | 289.25 | -2.3% | 156.3 | 310 / 273 | 349 / 167 | More Info
|
| AUROBINDO PHARMA | 744.05 | -2.0% | 173.4 | 776 / 740 | 791 / 281 | More Info
|
| ALKEM LABORATORIES | 2,395.95 | -1.9% | 8.2 | 2,510 / 2,375 | 2,882 / 1,660 | More Info
|
| CIPLA | 651.10 | -1.5% | 167.0 | 670 / 649 | 670 / 357 | More Info
|
| IOL CHEMICALS & PHARM. | 383.40 | -1.2% | 66.7 | 392 / 382 | 410 / 147 | More Info
|
| CADILA HEALTHCARE | 358.95 | -1.1% | 168.5 | 368 / 358 | 378 / 206 | More Info
|
| BIOCON | 389.60 | -1.0% | 186.4 | 400 / 389 | 400 / 211 | More Info
|
| SMS PHARMA | 43.50 | -1.0% | 8.9 | 45 / 43 | 62 / 24 | More Info
|
| IPCA LABS | 1,500.75 | -1.0% | 9.7 | 1,522 / 1,495 | 1,821 / 844 | More Info
|
| PROCTER & GAMBLE HEALTH | 4,245.30 | -0.8% | 0.3 | 4,304 / 4,232 | 5,121 / 2,928 | More Info
|
| STRIDES PHARMA SCIENCE | 416.60 | -0.7% | 109.3 | 426 / 415 | 547 / 271 | More Info
|
| AARTI DRUGS | 997.45 | -0.7% | 4.4 | 1,013 / 989 | 1,045 / 419 | More Info
|
| LUPIN | 902.30 | -0.6% | 135.1 | 924 / 899 | 924 / 505 | More Info
|
| VIMTA LABS | 81.40 | -0.6% | 10.9 | 85 / 81 | 194 / 51 | More Info
|
| PFIZER | 4,100.55 | -0.5% | 5.6 | 4,152 / 4,085 | 5,173 / 2,798 | More Info
|
| THYROCARE TECHNOLOGIES | 542.25 | -0.5% | 1.2 | 550 / 540 | 689 / 407 | More Info
|
| APOLLO HOSPITALS | 1,359.00 | -0.3% | 34.8 | 1,380 / 1,352 | 1,814 / 1,047 | More Info
|
| NEULAND LABS | 402.05 | -0.3% | 1.8 | 413 / 401 | 660 / 247 | More Info
|
| GRANULES INDIA | 184.25 | -0.3% | 85.0 | 188 / 183 | 189 / 84 | More Info
|
| SUN PHARMA | 494.15 | -0.2% | 747.8 | 511 / 492 | 511 / 315 | More Info
|
Circuit Breaker (up)
Circuit Breaker (down) * Mutual Funds that hold this stock
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- BSE A Group Gainers Today
- NSE Above Rs 20 Gainers Today
- BSE Above Rs 20 Gainers Today
- BSE Sensex Gainers Today
- BSE Small Cap Gainers Today
- BSE 500 Gainers Today
- BSE A Group Losers Today
- Most Active Stocks Rs 1 to 2
- NSE Above Rs 20 Losers Today
- ANALYSE:
- TCS
- HDFC BANK
- ITC LIMITED
- ONGC
- HINDUSTAN UNILEVER
- SBI
Today's Market
Sensex Ends 307 Points Higher; Metal and Telecom Stocks Witness Buying(Closing)
Indian share markets traded on a positive note throughout the day and ended higher, tracking positive global sentiments.
Related Views on News
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)
May 19, 2020 | Updated on May 19, 2020For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
CIPLA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 9, 2019 | Updated on Sep 9, 2019Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.
MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)
Mar 13, 2019Should you subscribe to the IPO of MSPC Limited?
More Views on NewsMost Popular
6 Charts Showing the State of Indian Financial Markets in 2020 (Sector Info)
May 26, 2020Six charts showing how Indian financial markets have performed in 2020 so far...
Why We Picked This Smallcap Stock for a Post Coronavirus World (Profit Hunter)
May 28, 2020Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.
What the RBI's Rate Cut Means for Options Traders (Fast Profits Daily)
May 25, 2020The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.
Who Will Be Crowned the 'Multibagger Blue Chip' of the Decade? (Profit Hunter)
May 25, 2020Will the mutlibagger blue chips of the past decade continue to rule the bourses?
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
S&P BSE HEALTHCARE
Jun 5, 2020 (Close)
S&P BSE HEALTHCARE 5-YR ANALYSIS
COMPARE COMPANY
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.